
Innovation & Devices
Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials
Two phase 3 trials found fewer moderate or severe COPD exacerbations with tozorakimab in current and former smokers, but candidate selection remains unsettled.
Rayan Salih · October 2, 2026 · 6 min


